About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Research Group on Status Epilepticus and Acute Seizures is a young and emerging team, consolidated in national and international clinical research and in the comprehensive and multidisciplinary approach to epilepsy. The scientific challenge of the group is based on understanding, improving and strengthening knowledge about the different fields of epilepsy and how to help solve problems related to epileptic seizures and their consequences.
Among the different projects of the group, it is worth mentioning the search for new biomarkers related to the mechanisms of epileptogenesis, obtaining tools and biomarkers to help diagnose status epilepticus and predict its prognosis, the acquisition of neuroimaging parameters and their relationship with the cognitive status of patients, and other studies to accelerate the diagnostic processes and optimize the therapeutic management of patients with drug-resistant epilepsy.
PMID: 37034728 Journal: Year: 2023 Reference: medRxiv. 2023 Sep 18:2023.03.27.23287713. doi: 10.1101/2023.03.27.23287713. Preprint. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Abraira, L; Ballve, A; Batzler, Anthony; Bianchi, Sevim B; Biernacka, Joanna M; Campos, D; Coombes, Brandon J; Cox, Nancy J; Davis, Lea K; Ehinmowo, Michael et al. DOI: 10.1101/2023.03.27.23287713
PMID: 37892809 Journal: Journal of Clinical Medicine Year: 2023 Reference: J Clin Med. 2023 Oct 22;12(20):6671. doi: 10.3390/jcm12206671. Impact factor: Publication type: Paper in international publication Authors: Abraira-Del Fresno, L; Barone, Paolo; Campos-Fernandez, D; De Bernardo, Maddalena; De Luca, Martina; Diana, Francesco; Fonseca-Hernandez, E; Gioia, Marco; Lallana-Serrano, S; Meler-Amella, P et al. DOI: 10.3390/jcm12206671
PMID: 37995538 Journal: EPILEPSY & BEHAVIOR Year: 2023 Reference: Epilepsy Behav. 2023 Nov 22;149:109531. doi: 10.1016/j.yebeh.2023.109531. Impact factor: Publication type: Paper in international publication Authors: Abraira, Laura; Adic, Filip; Adic, Nada Cemerlic; Aurelian, Rosca; Becker, David; Benedek, Imre; Benedek, Theodora; Berry, Colin; Birtolo, Lucia Ilaria; Bosserdt, Maria et al. DOI: 10.1016/j.yebeh.2023.109531
PMID: 38001636 Journal: Cancers Year: 2023 Reference: Cancers (Basel). 2023 Nov 12;15(22):5376. doi: 10.3390/cancers15225376. Impact factor: Publication type: Paper in international publication Authors: Abadias-Granado, Isabel; Abraira, Laura; Almagro, Manuel; Almenara-Blasco, Manuel; Arias-Santiago, Salvador; Banuls, Jose; Buendia-Eisman, Agustin; Campos-Fernandez, Daniel; Colmenero, Maria; De la Fuente-Meira, Sonia et al. DOI: 10.3390/cancers15225376
